Second dose of radioactive drug shows promise for tough prostate cancer

NCT ID NCT06288113

Recruiting now Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 33 times

Summary

This study tests whether giving a second round of a radioactive drug called 177Lu-PSMA-617 can help men with advanced prostate cancer that no longer responds to hormone therapy. The drug targets and delivers radiation directly to cancer cells. Participants must have already responded well to a first round of this treatment. The goal is to see if re-treatment can extend survival and control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UCLA / Jonsson Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90095, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CASTRATION-RESISTANT PROSTATE CARCINOMA STAGE IVB PROSTATE CANCER AJCC V8 STAGE IVB PROSTATE CANCER AJCC V8